Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Numab Therapeutics AG. (3/28/17). "Press Release: Numab and Ono Pharmaceutical Co., Ltd. Enter into a Research and Option Agreement". Pfäffikon.

Organisations Organisation Numab Therapeutics AG
  Group Numab (Group)
  Organisation 2 Ono Pharmaceutical Co., Ltd. (TSE: 4528)
  Group Ono Pharmaceutical (Group)
Products Product antibody cancer drug
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index term Index term Ono Pharmaceutical–Numab: antibody cancer drug, 201703– research + option agreem up to CHF258m + royalties for multi-specific antibody
Persons Person Middendorp, Oliver (Numab 201703 CBO + Co-Founder before Esbatech 2004–2010)
  Person 2 Habashita, Hiromu (Ono Pharmaceutical 201703 Corp Officer + Executive Director Discovery + Research)

Numab to receive up to CHF 258 million plus tiered royalties on sales

Numab Therapeutics AG (“Numab”) today announced a research and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”) for the identification of a multi-specific antibody candidate for development in immuno-oncology.

Under the agreement, Ono will obtain an option to acquire intellectual property rights to, and exclusive rights to develop and commercialize, the selected lead compound to be generated through this collaboration, which will exploit one of Ono’s novel therapeutic approaches in immuno-oncology. In exchange Numab will receive research funding and up to CHF 258 million in upfront and milestone payments plus tiered single to double digit royalties on sales.

Oliver Middendorp co-CEO of Numab, said: “We are extremely pleased to start our collaboration with Ono, a company with a track record of scientific excellence and innovation, and that most recently made its mark by launching a new era in cancer treatment with the development of the first anti-PD-1 antibody, Nivolumab/Opdivo.”

Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of Ono, said: “We highly value the capabilities of Numab’s multi-specific antibody platform. It is robust, and optimized to reproducibly yield product candidates with outstanding binding properties. We believe it is ideally suited to fuel our immuno-oncology drug discovery and consequently a multi-specific antibody to be generated through this collaboration will provide hope to sufferers of cancer.”

About Numab

Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immuno-oncology and immunology, and has a number of discovery partnerships with pharmaceutical companies. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile. For further information, visit

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to create innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas. For more information, please visit the company’s website at


Numab Therapeutics AG
Oliver Middendorp
CBO & co-CEO

Capricorn One
Hans Herklots
+41 79 598 7149

Record changed: 2019-06-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Numab (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top